Latest Breaking News On - Travis mickle - Page 1 : vimarsana.com

Zevra Therapeutics (ZVRA) Appoints Biopharma Veteran Wendy Dixon, Ph D , to Board of Directors

Zevra Therapeutics (ZVRA) Appoints Biopharma Veteran Wendy Dixon, Ph D , to Board of Directors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomWendyl dixonMatthewr ploosterWendy dixonTravisc mickleTravis mickleBristol myers squibbChris posnerIovance biotherapeutics incKempharm incSesen bio incDentsply internationalVoyager therapeutics incBoard of directors arivinas incDiamond therapeutics incArdea biosciences inc

Zevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph D , to Board of Directors

Zevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph D , to Board of Directors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomTravisc mickleWendyl dixonBristol myers squibbTravis mickleNichol ochsnerJennifer arcureChris posnerMatthewr ploosterWendy dixonFuriex pharmaceuticals incyteEuropean medicines agencyZevra therapeutics incDrug administrationCompany early access programDiamond therapeutics inc

KemPharm Appoints New Leadership - Global Genes

KemPharm Appoints New Leadership - Global Genes
globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.

Travis mickleMatthew ploosterRichard pascoeJoshua schaferMallinckrodt pharmaceuticalsAstellas pharmaceuticalsTakeda pharmaceuticalsUniversity of notre dameCognia corporationNorthwestern universityShuttle pharmaceuticalsRare diseaseNotre dame

KemPharm Gets FDA Orphan Drug Designation for Serdexmethylphenidate for Idiopathic Hypersomnia

The FDA has granted the Orphan Drug Designation to serdexmethylphenidate, KemPharm’s proprietary prodrug of d-methylphenidate for the treatment of idiopathic hypersomnia

United statesTravis mickleDrug administrationOrphan drug designationDrug designation

Serdexmethylphenidate Granted Orphan Drug Status for Idiopathic Hypersomnia

The FDA has granted Orphan Drug designation to serdexmethylphenidate (KP1077) for the treatment of idiopathic hypersomnia.

Travis mickleDrug administrationOrphan drug